Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)
Close on Nov 18, 2026Market cap $6.09BP/E –Yield –
Arrowhead Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Arrowhead Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $669.50M, up 16.8% year over year. For fiscal 2025 it was $829.45M, up 23258.2% from the year before. Over ten years it grew 115.6% a year on average. The highest annual figure on record is $829.45M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $829.45M | +23258.2% |
| FY2024 | Sep 30, 2024 | $3.55M | -98.5% |
| FY2023 | Sep 30, 2023 | $240.74M | -1.0% |
| FY2022 | Sep 30, 2022 | $243.23M | +75.9% |
| FY2021 | Sep 30, 2021 | $138.29M | +57.2% |
| FY2020 | Sep 30, 2020 | $87.99M | -47.9% |
| FY2019 | Sep 30, 2019 | $168.80M | +945.7% |
| FY2018 | Sep 30, 2018 | $16.14M | -48.6% |
| FY2017 | Sep 30, 2017 | $31.41M | +19736.5% |
| FY2016 | Sep 30, 2016 | $158.33K | -58.6% |
| FY2015 | Sep 30, 2015 | $382.00K | +118.3% |
| FY2014 | Sep 30, 2014 | $175.00K | -39.7% |
| FY2013 | Sep 30, 2013 | $290.27K | +97.6% |
| FY2012 | Sep 30, 2012 | $146.88K | -50.4% |
| FY2011 | Sep 30, 2011 | $296.14K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $75.25M | +171.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $73.74M | -86.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $264.03M | +10461.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $256.47M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $27.77M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $542.71M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $2.50M | -29.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $0 | -100.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $0 | -100.0% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $0 | -100.0% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $3.55M | -94.3% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $16.10M | -49.0% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $15.83M | -51.2% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $146.27M | -3.6% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $62.55M | +127.9% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $31.58M | -17.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $32.41M | -29.4% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $151.81M | +362.7% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $27.44M | +28.8% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $38.28M | +401.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $45.89M | +67.6% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $32.81M | +39.4% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $21.30M | -27.7% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $7.63M | -82.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $27.38M | -35.9% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $23.53M | -51.1% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $29.46M | -15.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $43.29M | +284.7% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $42.70M | +5770.0% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $48.15M | +7306.0% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $34.66M | +887.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $11.26M | +29.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $727.38K | -92.2% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $650.13K | -92.8% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $3.51M | -19.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $8.71M | +27784.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $9.34M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $8.99M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $4.37M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $31.25K | – |
See a number that looks wrong?